![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.161.077 |
Chemical and physical data | |
Formula | C22H21NO3 |
Molar mass | 347.414 g·mol−1 |
3D model (JSmol) | |
| |
|
GW9508 is an experimental drug which acts as a mixed agonist for the free fatty acid receptors FFAR1 (GPR40) and FFAR4 (GPR120). It is around 60x more potent as an agonist at FFAR1, [1] but has nevertheless often been used as a model agonist for FFAR4 especially in tissues which lack FFAR1 or in the presence of FFAR1 antagonists, [2] due to a historical lack of availability of highly selective FFAR4 agonists. [3] It has antiinflammatory effects [4] [5] [6] and has also been used to study the role of FFAR1 and FFAR4 in various processes such as regulation of insulin [7] and ghrelin [8] release, immune system function, [9] [10] and maintenance of bone density. [11]